Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network

Abstract

Signal transducers and activators of transcription (STAT) proteins were described as a family of latent cytosolic transcription factors whose activation is dependent on phosphorylation via growth factor- and cytokine-membrane receptors including interferon and interleukin, or by non-receptor intracellular tyrosine kinases, including Src. A vast majority of natural substances are capable of modulating mitogenic signals, cell survival, apoptosis, cell cycle regulation, angiogenesis as well as processes involved in metastasis development. The inhibition of STAT3 phosphorylation by natural and dietary compounds leads to decreased protein expression of STAT3 targets essentially involved in regulation of the cell cycle and apoptotic cell death. This review details the cell signaling pathways involving STAT transcription factors as well as the corresponding compounds from nature able to interfere with this regulatory system in human cancer.

The family of STAT transcription factors

Structure and function

STAT (signal transducers and activators of transcription) proteins were originally described as a family of cytoplasmic transcription factors. In mammals, seven members of this family, each consisting of 750–900 amino acids, have been identified: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. These transcription factors act as dimers (homo- or hetero-dimers), and their activation is dependent on their phosphorylation or via membrane receptors stimulated by either extracellular factors, including interferon (IFN) and interleukin (IL-6), or by intracellular kinases independent of receptors, including Src. Activation of STATs is usually transient and highly regulated. STAT proteins contain seven conserved structural and functional domains (Fig. 1a) (Schindler and Plumlee 2008).

Fig. 1

a Schematic representation of the structural domains of STAT proteins, adapted from (Liu et al. 2002). The STAT protein contains an N-terminal domain (ND) responsible for stabilizing the binding of STAT dimers to DNA. The “coiled-coil” domain (CCD) is involved in interactions with other proteins. The DNA binding domain (DBD) allows physical contact with the STAT response elements in the promoter of target genes. The linker domain connects the DBD to the “Src homology 2” domain (SH2) and is important in the dimerization of STAT proteins. A tyrosine residue (Y) in the TAD domain is phosphorylated and interacts with the SH2 domain of another monomer. The C-terminal TAD area is responsible for the transcriptional activation of target genes. Areas in purple represent the different sites of action of specific inhibitors of STAT3 that have been recently identified. b Schematic representation of the structural domains of JAK proteins, adapted from Braunstein et al. (2003). The N-terminal region of the JAK protein contains the JH3–JH7 domains (shown in purple) that are involved in protein binding with the receptor. Next, the JH2 domain (shown in blue) corresponds to the domain pseudokinase necessary to regulate the catalytic activity of JH1. The JH1 domain is found in the C-terminal and contains the kinase activity. This domain contains two tyrosines that play an important role in protein kinase activity

First, the amino terminal NH₂ domain is involved in the dimerization of STAT proteins and in the stabilization of the interaction established between these dimers and DNA response elements (Braunstein et al. 2003; Mertens et al. 2006). The coiled-coil domain is responsible for controlling the process of import and export of proteins into and from the nucleus (Schindler et al. 2007). The domain that binds DNA, or the DBD (DNA binding domain), is involved in the physical interaction with STAT3-response elements in the promoters of target genes. With the exception of STAT2, all activated STAT homodimers bind directly to a palindromic sequence, the GAS (IFN-gamma-activated site), TTTCCNGGAAA (Becker et al. 1998). The “linker” domain localizes the active dimer to the DNA binding site. The transcriptional activation domain (TAD) contains sites of phosphorylation of serine residues that allow the recruitment of coactivators such as RNA polymerase II, histone acetyltransferase (HAT) (Paulson et al. 2002), histone deacetylase (HDAC) (Rascle et al. 2003) and chromatin modification complexes.

Finally, two sites are particularly critical for the activity of STAT. These are the SH2 domain (Src homology 2, amino acids 575–680), which is linked to the DBD by the linker domain, and a conserved tyrosine close to residue 700. The SH2 domain is highly conserved and allows for the recruitment of specific STAT proteins to the intracellular chains of membrane receptors and participates in the formation of active dimers from STAT monomers. The tyrosine residue close to position 700 in the inactive STAT monomer is phosphorylated by protein kinases of the Janus family kinases (JAK) associated with specific membrane receptors that promote the recruitment of this monomer. Interaction with STAT results from the stimulation of membrane receptors following an extracellular signal that is transduced by cytokines, growth factors and other polypeptide ligands.

The JAK/STAT signaling pathway

The interaction between ligands and specific receptors, which are associated with JAK proteins, triggers receptor dimerization. This dimerization is followed by transphosphorylation, which is required for the activation of JAK proteins. Receptors associated with the JAK/STAT signaling pathway are class I (hematopoietin) and class II (interferon) cytokine receptors. These receptors have a transmembrane domain, and their extracellular region binds the ligand (cytokine), whereas their intracellular domain is used for the interaction with JAK and STAT. The JAK/STAT signaling pathway is highly conserved during evolution. It was first identified in vertebrates, where this signal transduction pathway was found to be activated by cytokines.

JAK proteins belong to a family of intracellular tyrosine kinases with a molecular weight of 120–140 kDa. In mammals, this family of proteins is composed of four members: JAK1, JAK2 and Tyk2, which are widely expressed in a variety of different cell types, and JAK3, which is mainly found in hematopoietic cells. JAK was first identified in 1989 and was termed Just Another Kinase. Later, this protein was renamed Janus Kinase (JAK), after the Roman god, because it has a kinase domain and a “kinase-like” domain that regulates the kinase domain (Pellegrini and Dusanter-Fourt 1997).

These proteins possess various domains, as shown in Fig. 1b. The C-terminus of the protein, JAK homology domain JH1 for domain 1, carries the kinase activity. This domain is structured as a loop involving two tyrosines that play a very important role in regulating kinase activity. For example, for JAK2, tyrosine residues 1007 and 1008 are phosphorylated. A single mutation of tyrosine 1007 suppresses the tyrosine kinase activity of JAK2 (Heinrich et al. 1998). The JH2 kinase-like domain precedes the JH1 domain. This domain may affect kinase activity, but there is no clear explanation found in the literature. Within the N-terminus of the protein, the 5 domains ranging from JH3 to JH7 are involved in the interaction with the receptor. These domains contain conserved sequences found in various JAK proteins (Pellegrini and Dusanter-Fourt 1997).

JAK proteins phosphorylate the cytoplasmic domain of the receptor at tyrosine residues (Fig. 2). These phosphorylated residues are important in recognizing the monomeric and cytoplasmic STATs. STAT proteins are recruited to the phosphorylated tyrosine receptor via their SH2 domain and are then phosphorylated by JAK at tyrosine 705; then, the phosphorylated STAT monomers dimerize. The interaction between the two monomers is established by an interaction between the SH2 domains and phosphorylated tyrosines. The dimer is then imported into the nucleus by importins (Benekli et al. 2009). In the nucleus, active STAT will bind to specific regulatory elements (GAS) within regulatory promoter sequences of target genes. JAK proteins can then activate the transcription factor STAT, but it is possible that other proteins may also activate this factor. For example, the protein tyrosine kinase Src may cause dimerization of the transcription factor STAT also resulting in the activation of selected target genes (Darnell 1997).

Fig. 2

The JAK/STAT signaling pathway. Ligand binding to the membrane receptor leads to receptor dimerization (1) and activation of associated JAK proteins (2). JAK phosphorylates the receptor (3) to recruit and phosphorylate cytoplasmic STAT factors (4). Phosphorylation of STAT factors leading to their dimerization (5). As a dimer, STAT will be translocated into the nucleus (6) to specifically bind to DNA at the GAS (IFN-gamma-activated site). The STATE dimer activates the transcription of its target genes (7). This figure presents STAT3 and its target genes in the nucleus as an example

Involvement of STAT3 in cancer

The STAT family of transcription factors plays an important role in many cellular events, including differentiation, proliferation, inflammation and the immune response. In fact, disruption of the mechanism leading to constitutive activation of STAT is considered to be a cancer-promoting factor (Benekli et al. 2003).

Constitutive activation of STAT is associated with malignant transformation induced by various oncoproteins that are tyrosine kinases, such as Src (sarcoma viral oncogene homolog), Bcr-Abl (breakpoint cluster region-Abelson) or EGFR (epidermal growth factor receptor) (Ilaria and Van Etten 1996; Ozawa et al. 2008). The target genes of STATs, such as cyclins D1/D2, Myc, Bcl-xL and Mcl-1 among others, appear to contribute to oncogenesis by activating cell cycle and inhibiting apoptosis (Epling-Burnette et al. 2001; Ozawa et al. 2008). The constitutive activation of these transcription factors indeed generates a deregulation of growth and cell survival, invasion of tumor cells and thus the formation of metastasis, an increase in angiogenesis and suppression of immune surveillance of the tumor. STAT3 transcription factor is frequently activated in cell lines and leukemic blasts of patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) (Spiekermann et al. 2001). Moreover, STAT3 has also been involved in a wide range of cancer types including multiple myelomas (MM), cutaneous T-cell lymphomas (CTCL), hepatocellular carcinomas (HCC), cholangiocarcinomas (CCA), as well as prostate and pancreatic cancers.

Genetic and biochemical studies have highlighted the key role of STAT3 in signal transduction induced by cytokines, including IL-6, IL-10 and IFN. Knockout mice for STAT3 exhibit early embryonic mortality consistent with its multiple activities, and STAT3 gene extinction in specific tissues has been associated with an inflammatory response, developmental abnormalities and decreased oncogenic potential. Instead, hyperactivation of STAT3 has been associated with immunosuppression and cellular transformation. Compared to healthy cells, where STAT activation is highly regulated, some solid tumor and hematological cancers maintain constitutive activity of STAT3 protein phosphorylation. Accordingly, a clear link between the aberrant activation of STAT3 and tumor formation has been depicted in the literature. Indeed, it was shown that constitutively active STAT3 could cause the inhibition of tumor suppressive activity of p53 by binding to the p53 promoter (Niu et al. 2005). In addition, recent studies have shown that activation of the STAT3 gene leads to the overexpression of AKT, a key target of phosphatidylinositol 3-kinase (PI3K) that is constitutively activated in acute myeloid leukemia (AML). PI3K regulates cell survival and resistance to chemotherapy via pathways that involve mitogen-activated protein kinase (MAPK) as well as transcription factors NF-kB and p53 (Grandage et al. 2005). STAT3 is mainly phosphorylated by JAK2 in combination with a membrane receptor stimulated by a cytokine.

In leukemia, the JAK2 kinase presents a Valine 617 → phenylalanine (V617F) mutation in the JH2 kinase-like domain. This mutation confers either hypersensitivity or independence to hematopoietic cytokines. Moreover, abnormal proliferation and survival of stem cells is affected by this mutation. In 50% of cases of acute myeloid leukemia (AML), STAT3 is constitutively active and this activation leads to many cellular processes, such as cell resistance to apoptosis (Zhao et al. 2011). Moreover, the survival of patients without constitutive phosphorylation of STAT3 has significantly increased. According to Staerk et al. (2007), the V617F mutation suppresses the inhibitory function of the JH2 pseudokinase domain over the kinase domain (JH1). Concerning this mutation, two assumptions were made. The first assumption was that mutant JAK2 could interact normally with the receptor and the complex formed between the receptor and JAK2 V617F entity would be considered to be constitutively active. The second was that the V617F mutation could trigger pathological activation, thereby causing persistent phosphorylation of JAK2 V617F tyrosine at 1007, or at one or more of the 49 known tyrosines within the primary sequence of JAK2. The human erythroleukemia cell line HEL presents the V617F mutation within the JAK2 gene and represents an interesting model to study this mutation and the cellular dysfunctions that it generates. This cell line was established from cells collected in the pleural fluid of a 30-year-old patient suffering from acute myeloid leukemia (AML) (Martin and Papayannopoulou 1982).

Multiple myeloma (MM) is a clonal B-cell neoplasm characterized by an accumulation of neoplastic plasma cells that leads to reduced patient survival (Damber and Aus 2008). As for many types of leukemia, STAT3 is considered to be one of the main factors involved in the pathogenesis and chemoresistance of MM, therefore resulting in a high mortality rate. Indeed, MM cells have been shown to express constitutive activated STAT3 in correlation with the overexpression of the anti-apoptotic proteins Bcl-x_L (Catlett-Falcone et al. 1999; Grad et al. 2000; Tu et al. 1998) and Bcl-2 (Pettersson et al. 1992). On the other hand, recent studies have revealed a key role for chronic inflammation in the different stages of prostate cancer progression (Bhutani et al. 2007). Indeed, prostate cancer proliferation, survival, invasion, metastasis and angiogenesis are linked to the NF-κB, STAT3, AKT and COX-2 signaling pathways (Chan et al. 2010; Shanmugam et al. 2011b). However, NF-κB and STAT3 have been particularly implicated in cell survival, metastasis and angiogenesis of prostate tumors (Gojo et al. 2002). Moreover, STAT3 is often constitutively activated in hepatocellular carcinoma (HCC) (Liu et al. 2002; Niwa et al. 2005) where it induces cell growth and inhibits apoptosis. Interestingly, a clear link between hepatitis C virus (HCV), STAT3 activation and HCC development has been reported (Waris and Siddiqui 2005; Yoshida et al. 2002). As described by many studies, STAT3 represents a good candidate as a target in HCC patients for therapeutic agents including natural compounds (Li et al. 2010; Rajendran et al. 2011a, b; Tan et al. 2010).

Inhibition of STAT

Introduction

To reduce the aberrant activation of STAT proteins, there are several treatment strategies that target these proteins. In particular, it is possible to inhibit specific membrane receptors, tyrosine kinases, mRNAs and proteins that activate STAT. For several years, synthetic compounds inhibited STAT factors by various molecular mechanisms. These inhibitors block the translocation step of the active dimer from the cytoplasm to the nucleus and act at the point where the dimer binds to DNA. Many naturally occurring substances have also appeared in the list of molecules that are potentially active antitumor agents through specific inhibition of STAT.

Constitutive expression of activated STAT factors leads to tumor promotion; therefore, specific inhibition of these mechanisms should preferentially target cancer cells without affecting other cells. Therapeutic strategies considered for the treatment of leukemia and non-hematological cancers (Jing and Tweardy 2005) would specifically target activation of STAT factors, such as the inhibition of transmembrane receptors and associated downstream signaling, or more directly STAT activity. A specific antibody, rituximab, could inhibit the CD20 transmembrane antigen expressed by B cells in non-Hodgkin lymphoma cells, leading to the inhibition of constitutive STAT3 phosphorylation (Alas and Bonavida 2001). These results demonstrate the relevance of a strategy to inhibit STATs via membrane receptors.

The inhibition of tyrosine kinases that are associated with receptors by specific inhibitors has been particularly studied in recent years. The inactivation of JAK2 by the tyrphostin AG490 is an example of the potential effectiveness of such a treatment to suppress constitutive STAT3 phosphorylation. Indeed, this molecule leads to the arrest of leukemic cell proliferation in vitro and in vivo (Meydan et al. 1996), and apoptosis of U266 myeloma cells (Jing and Tweardy 2005). Another tyrosine kinase inhibitor already in clinical use in the treatment of Bcr-Abl positive leukemia, imatinib, has been shown to have an inhibitory effect on the expression of the anti-apoptotic gene, Bcl-xL, which is a target gene of STAT5 (Horita et al. 2000). In addition, targeting very specific STAT factors can be achieved through the use of competitor peptides to prevent formation of STAT dimers (Turkson et al. 2001). Other strategies that use highly selective inhibitors of STAT mRNA include single-strand oligonucleotides or siRNA (small interfering RNA) (Lee et al. 2004).

Inducing in vitro growth arrest of tumor cells and apoptosis as well as tumor regression in vivo by inhibition of the constitutive activity of STAT3 is then conceivable by pharmacological or genetic approaches. Selected examples of STAT3 inhibitors are listed in Table 1 (Yue and Turkson 2009). Some molecules will directly target the SH2 domain of the protein to prevent dimer formation and thus the formation of active STAT3. For example, a non-peptide small molecule called Stattic selectively inhibits STAT3 by directly binding to the SH2 domain (Schust et al. 2006). The SH2 domain of STAT3 is indeed critical for the activation of STAT3 and its translocation to the nucleus. Therefore, Stattic has a selective inhibitory effect on activation, dimerization and translocation to the nucleus, while also increasing induction of apoptosis.

Table 1 Inhibitors of STAT3 synthesis, their targets, mode of inhibition and cellular effects, adapted from Yue and Turkson 2009)

Other inhibitors, including CPA-1, CPA-7 (Turkson et al. 2004) or IS3 295 (Turkson et al. 2005), act at the level of the DBD domain responsible for binding of STAT3 to DNA. They block the transcriptional activation of STAT3 target genes. Inhibitors that inhibit the transcriptional activity of STAT3 without affecting phosphorylation may also target the N-terminus. In addition, the use of siRNA and antisense RNA induced apoptosis of tumor cells and tumor regression (Lee et al. 2004). Other strategies inhibit steps upstream of the activation of STAT3. For example, it is possible to use inhibitors of tyrosine kinase to prevent phosphorylation of STAT3.

Natural STAT3 inhibitors and cancer

A vast majority of natural substances are capable of modulating mitogenic signals, cell survival, apoptosis, cell cycle regulation, angiogenesis as well as processes involved in metastasis development. In addition, many natural compounds have been studied in order to elucidate their roles in the signaling pathways implicated in cancer. The chemical structures of the natural compounds with inhibitory activity on STAT3 cited in this review (in italics) are presented in the Fig. 3. Studies have shown that the natural compound, cryptotanshinone (Shin et al. 2009), is able to inhibit the rapid phosphorylation of tyrosine 705 in STAT3 and thereby blocks the growth of prostate cancer-derived cells. The inhibition of STAT3 phosphorylation leads to decreased protein expression of STAT3 targets, including cyclin D1, which regulates the cell cycle, survivin, which is responsible for the inhibition of caspase activation, or the anti-apoptotic protein Bcl-xL, which belongs to the Bcl2 protein family and is involved in the survival of cancer cells. This natural compound may also bind directly to STAT3 molecules at the SH2 domain-level to block the formation of STAT dimers. Likewise, capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), one of principal ingredients of chili from the plant Capsicum (Solanaceae), can suppress carcinogenesis of the skin, colon, lung, tongue and prostate. Bhutani et al. demonstrated the mechanisms of inhibition of STAT3 in multiple myeloma cells. According to these studies, capsaicin is able to block both the inducible and the constitutive activation of STAT3; this effect is correlated with downregulation of the expression of the genes involved in cell survival, proliferation and angiogenesis (Bhutani et al. 2007). Furthermore, the inhibition of STAT3 activation can significantly reduce the pool of nuclear STAT3. This work also showed that capsaicin is able to suppress the dose-dependent binding activity of STAT3 to DNA and that this compound may also inhibit the constitutive activation of several kinases, such as JAK1, c-Src and ERK.

Fig. 3

Chemical structures of different dietary STAT3 inhibitors

Multiple myeloma

Many chemotherapeutic drugs have been used for many years to treat MM patients with variable efficiencies; these drugs include melphalan, prednisone, alkylating agents, Vinca alkaloids and more recently, thalidomide and its derivatives as well as the proteasome inhibitor bortezomib. Moreover, patients frequently develop resistance to these treatments (Dimopoulos et al. 2003).

STAT3 is considered to be one of the main factors involved in the pathogenesis and chemoresistance of MM, therefore resulting in a high mortality rate. Besides its effect on STAT proteins in leukemia cells, curcumin was also reported to be a reversible inhibitor of constitutive STAT3, but not STAT5 phosphorylation, in human MM cells (Bharti et al. 2003). This was correlated with the inhibition of STAT3 nuclear translocation in MM cells. Despite its structural similarities with the STAT3 inhibitor AG490, curcumin was shown to be more efficient as a STAT3 inhibitor in the U266 cell line (Meydan et al. 1996). On the other hand, the triterpene celastrol, a natural compound from a Chinese herbal product, has been studied as an antiproliferative molecule of MM cells. Celastrol has various molecular targets, and its ability to modulate the expression of numerous proteins related to a wide range of cellular activities including pro-inflammatory cytokines, adhesion molecules, proteasome activity, topoisomerase II, potassium channels and heat shock response has been reported (Kannaiyan et al. 2011a). Kannaiyan et al. (2011b) reported that proliferation of MM cell lines was inhibited by celastrol in correlation with the inhibition of constitutive and induced activation of STAT3. The effect of celastrol occurred in cells both sensitive and resistant to bortezomib. Furthermore, it enhanced bortezomib- and thalidomide-mediated apoptosis in MM cells, concomitantly in order to downregulate STAT3 target genes, including cyclin D1, Bcl-2, Bcl-xL, survivin, XIAP and Mcl-1. According to these results, the authors suggested that celastrol could potentially be used in the treatment of MM and other hematological malignancies (Fig. 4).

Fig. 4

JAK/STAT signaling pathway targeted by different inhibitors. These inhibitors target the following points in the JAK/STAT signaling pathway: constitutive activation of JAK2, STAT3 phosphorylation, formation of the STAT dimer and binding activity of STAT3 to DNA. In contrast, the phosphatase SHP-1 can be activated

Acetyl-11-ketoh-boswellic acid (AKBA), another natural triterpenoid, is isolated from the Indian frankincense Boswellia serrata and exhibits anti-inflammatory and anticancer activities. AKBA was reported to be an inhibitor of both constitutive and inducible STAT3 activation through the induction of the Src homology region 2 domain–containing phosphatase 1 (SHP-1). This effect correlated with an inhibitory activity on JAK and c-Src. Regarding the effect of this molecule, a downregulation of STAT3 target genes was expected, resulting in the suppression of proliferation and induction of apoptosis in MM cells. However, besides its effect on MM cells, AKBA was also shown to suppress the growth of glioma, colon cancer, prostate and leukemic cells. These effects on multiple cancer targets can occur through the inhibition of the extracellular signal regulated kinase 1 and 2 (ERK1/2) phosphorylation, NF-κB pathway inhibition via IκB kinase (IKK) as well as topoisomerase I inhibition (Glaser et al. 1999; Hoernlein et al. 1999; Liu et al. 2002; Park et al. 2002; Shao et al. 1998; Syrovets et al. 2005). These observations suggest that AKBA does not specifically affect STAT3 activity but has a wide field of action.

Similarly, the main component isolated from the medicinal plant Nigella sativa, thymoquinone (TQ), was shown to inhibit both constitutive and IL-6-induced STAT3 phosphorylation. Moreover, TQ potentiated the apoptotic effects of thalidomide and bortezomib in MM cells. Besides its inhibitory effect on STAT3-target genes, including pro-apoptotic ones, the mechanism of action of this natural compound has been proposed to involve the inhibition of c-Src and JAK2 activation as well as a protein tyrosine phosphatase. Indeed, while TQ induced the expression of Src homology-2 phosphatase 2 in correlation with the inhibition of STAT3 phosphorylation, the phosphatase inhibitor vanadate reversed the TQ-induced downregulation of STAT3 activation (Li et al. 2010). Similar mechanisms were observed in MM cells with the natural chalcone butein, which inhibited STAT3 activation by inducing expression of the tyrosine phosphatase SHP-1. Indeed, the deletion of the SHP-1 gene by small interfering RNA abolished the ability of butein to inhibit STAT3 activation (Pandey et al. 2009).

Atiprimod, which is an anti-inflammatory compound that is well tolerated in patients with rheumatoid arthritis, is among the natural products that are able to block MM cell proliferation. Atiprimod, a cationic amphiphilic molecule from the azaspirane family of compounds, was shown to induce accumulation of several MM cell lines at the sub-G₀/G₁ phase of the cell cycle (Amit-Vazina et al. 2005). Atiprimod inhibited the JAK/STAT pathway, leading to the inhibition of STAT3 phosphorylation. As the constitutive activation of STAT3 in myeloma cells results in the upregulation of anti-apoptotic proteins, the effect of Atiprimod on Bcl-2, Bcl-XL and Mcl-1 expression has been assessed in MM cell lines (Catlett-Falcone et al. 1999), and as expected, this compound was found to downregulate the expression of these proteins. Moreover, Atiprimod inhibited IL-6 production, which is involved in MM proliferation through STAT3 activation, resulting in the induction of apoptosis in U266-B1 myeloma cells, which express constitutively active NF-κB and STAT3. However, NF-κB expression was also inhibited in Atiprimod-treated MM cells, independently of STAT3, suggesting a role for NF-κB in the mechanism of action of Atiprimod.

Interestingly, those authors confirmed the effects of Atiprimod on myeloma colony culture assays. Fresh BM samples obtained from five patients with newly diagnosed MM were tested, and Atiprimod suppressed the growth of myeloma colony-forming cells in a dose-dependent manner (Amit-Vazina et al. 2005).

The chalcone butein induced the expression of the tyrosine phosphatase SHP-1, and deletion of the SHP-1 gene by small interfering RNA abolished the ability of butein to inhibit STAT3 activation, suggesting a critical role for SHP-1 in the action of this chalcone (Pandey et al. 2009).

Cutaneous T-cell lymphoma (CTCL)

Furthermore, a study focusing on the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL) cell lines and peripheral blood mononuclear cells (PBMCs) from patients has been reported (Zhang et al. 2010). Curcumin caused more apoptosis in PBMCs from CTCL patients than from healthy donors. At the same concentrations (5–20 μM), curcumin induced apoptosis in a time- and dose-dependent manner in MJ-, Hut78- and HH CTCL-derived cell lines. This study suggested that curcumin induced apoptosis in CTCL cells in association with the downregulation of STAT-3 and NF-κB signaling pathways. Indeed, whatever the cell lines or patients’ PBMCs, STAT-3 protein and mRNA expression levels decreased after curcumin treatment. Moreover, STAT-3 phosphorylation was inhibited and its target genes, bcl-2 and surviving, were downregulated. In addition, curcumin activated caspase-3 and induced PARP cleavage.

Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Currently, the first-line drugs used for HCC include doxorubicin, fluorouracil, cisplatin and mitomycin, but most of these are non-selective cytotoxic molecules with significant side effects. Therefore, it is very important to identify new effective drugs. Among natural compounds from a variety of plants, diosgenin (Li et al. 2010), β-escin (Tan et al. 2010), butein (Rajendran et al. 2011b) and γ-tocotrienol (Rajendran et al. 2011a) were reported to inhibit proliferation and to induce apoptosis of HCC cells concomitantly in order to downregulate various STAT3-regulated gene products, including cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1 and VEGF. These four natural molecules inhibited constitutive and inducible activation of STAT3 through the inhibition of c-Src, JAK1 and JAK2 activation. The pentacyclic triterpenoid β-escin was recently found to exhibit significant antitumor effects in human hepatocellular carcinoma both in vitro and in vivo (Zhou et al. 2009). In addition, this effect of β-escin has also been reported to suppress colonic aberrant crypt foci formation in rats and to inhibit growth of colon cancer cells (Patlolla et al. 2006). On the other hand, diosgenin and butein were shown to inhibit P-STAT3 through the induction of phosphatases. Diosgenin, a steroidal saponin isolated from fenugreek, induced the expression of Src homology 2 phosphatase 2 (SH-PTP2) in correlation with the downregulation of constitutive STAT3 activation in HCC cells (Li et al. 2010). As previously described in MM cells, the butein-induced inhibition of P-STAT3 involved SHP-1 activation (Pandey et al. 2009), whereas a phosphatase role for this natural chalcone has not been reported in HCC cells. Interestingly, both diosgenin and butein potentiated the apoptotic effects of paclitaxel and doxorubicin in HCC cells. Moreover, butein inhibited the growth of human HCC xenograft tumors in male athymic nu/nu mice when administered intraperitoneally (Rajendran et al. 2011b). These authors suggested that these compounds are interesting as novel blockers of the STAT3 activation pathway with a potential role in the treatment of HCC.

Cholangiocarcinoma

Results recently reported by Prakobwong et al. (2011) suggested that curcumin exhibits an anti-cholangiocarcinoma (CCA) potential by suppressing various events involved in multiple steps of carcinogenesis, including its ability to suppress pro-inflammatory pathways. CCA is a major health problem in southeastern Asia because it causes the formation of highly metastatic tumors linked to liver fluke infection and consumption of nitrosamine-contaminated foods.

By using animal models infected with the liver fluke Opisthorchis viverrini and submitted to N-nitrosodimethylamine administration, the authors investigated the effect of a curcumin-supplemented diet on CCA development. Under these conditions, there was a significant reduction in the incidence of CCA and an increase in the survival of animals. These observations were in correlation with the suppression of STAT-3 activation as well as of the transcription factors NF-κB and AP-1. Moreover, a reduction in the expression of the pro-inflammatory proteins COX-2 and iNOS was also observed. As expected, curcumin induced caspase activation and poly (ADP-Ribose) polymerase (PARP) cleavage while it suppressed the expression of STAT3 target genes, including proteins related to cell survival (Bcl-2 and Bcl-xL), proliferation (cyclin D1 and c-myc) and angiogenesis (vascular endothelial growth factor, VEGF).

Prostate cancer

Recent studies have revealed a key role for chronic inflammation in the different stages of prostate cancer progression (Damber and Aus 2008). Indeed, prostate cancer proliferation, survival, invasion, metastasis and angiogenesis have been reported to be linked to the NF-κB, STAT3, AKT and COX-2 signaling pathways (Grivennikov and Karin 2010; Yu et al. 2009). However, NF-κB and STAT3 have been particularly implicated in prostate tumor cell survival, metastasis and angiogenesis (Li and Sethi 2010). A natural compound, the pentacyclic triterpenoid ursolic acid (UA) (3 β-hydroxy-urs-12-en-28-oic-acid) (Liu 1995), has been reported to be a potent inhibitor of constitutive and inducible STAT3 as well as NF-κB activation in prostate cancer cells (Shanmugam et al. 2011b). The authors also showed that UA significantly suppressed the growth of prostate cancer xenografts in vivo while it was previously reported to be able to inhibit tumor promotion, metastasis, angiogenesis and proliferation of a variety of tumor cells, including human multiple myeloma cells (Pathak et al. 2007) melanoma cells (Manu and Kuttan 2008) and breast cancer cells (Kassi et al. 2009).

Predictive analysis using a virtual tumor cell platform that allows for the determining of the primary target of UA in the prostate cancer cells showed that UA mediates an increase in the apoptotic phenotype by inhibiting STAT3 as well as NF-κB activity. Moreover, by using human androgen-independent DU145 and androgen-dependent LNCaP prostate cancer cell lines, Shanmugam et al. confirmed that UA inhibited cell proliferation and induced apoptosis in these prostate cancer cells. These effects were correlated with the inhibition of the canonical NF-κB signaling pathway as well as STAT3 phosphorylation through the upstream inhibition of JAK2 and Src activation. As expected, the effect of UA resulted in the downregulation of genes involved in survival and angiogenesis (Shanmugam et al. 2011b). Interestingly, the bioavailability of UA or its metabolites in mice serum was evaluated in this study. Results revealed that UA did not generate any metabolites in the serum and that the concentration of UA was higher than the concentration required to reach in vitro effects. Finally, the circulating concentration was appropriate to trigger inhibition of prostate tumor growth in nude mice. The effects of UA were extended to antimetastatic effects through the suppression of CXCR4 expression in prostate cancer both in vitro and in vivo (Shanmugam et al. 2011a).

Pancreatic cancer

Regarding pancreatic cancer, the work of Sun et al. (2010) showed that cucurbitacin E of the family of triterpenoids isolated from plants can reduce the phosphorylation of STAT3, leading to inhibition of cell growth, increased expression of p53 and induction of apoptosis of cancer cells. Indeed, p53 can arrest cell cycle progression at different points and induce apoptosis of cells whose growth has become uncontrolled. It is already known that cucurbitacin E has antiproliferative activity in the case of breast, lung and prostate cancer. Earlier work by Sun et al. (2005) had highlighted the fact that this compound acts at the level of lung cancer cells through inhibition of cancer cell growth and induction of apoptosis through downregulation of phosphorylated STAT3.

Leukemia

In the case of chronic myeloid leukemia, cucurbitacin B from herbaceous plants, belonging to the Cucurbitaceae family, is able to suppress the activation of STAT3. On the basis of the work by Chan et al. (2010), this natural compound can suppress activation of STAT3, resulting in inhibition of cell growth. This phenomenon can be explained by cell cycle arrest or induction of apoptosis. Also in the case of chronic myeloid leukemia, the work of Blasius et al. (2006) showed that curcumin, which is the main pigment derived from the roots of Curcuma longa, also known as turmeric, may inhibit the transcription factor STAT3. This work led to the fact that curcumin is capable of reducing the expression of STAT3 target genes, such as JAK2, v-src, a viral oncogene or cyclin D1, which is involved in regulating the cell cycle. This natural compound plays an important role in the induction of the apoptosis of cancer cells through inhibition of the expression of glutathione S-transferase P1-1 (Duvoix et al. 2003), implicated in the detoxification of the cell. Curcumin is in fact implicated in the inhibition of many stages of cancer development, including cell proliferation, angiogenesis and metastasis, by modulating expression and activity of different cell signaling mediators (Kunnumakkara et al. 2008). Besides its effect on STAT3 activity in HCC cells, Sorafenib also showed efficiency in chronic lymphocytic leukemia (CLL) cells, which is the most frequent leukemia. CLL is characterized by an accumulation of monoclonal mature B cells in blood, secondary lymphoid tissues and the marrow. Treatments of mononuclear cells from marrow aspirates of CLL patients led to inhibition of B-RAF, C-RAF, ERK and STAT3 phosphorylation in correlation with Mcl-1 downregulation and resulting in caspase-dependent apoptosis (Fecteau et al. 2011). Furthermore, flavopiridol, formerly L86-8275 or HMR 1275, is an hemi-synthetic flavonoïd derivative from rohitukine, an alkaloid isolated from the Indian plant Dysoxylum binectariferum (Sedlacek et al. 1996). Flavopiridol was first described as a cyclin-dependent kinase inhibitor (Carlson et al. 1996). Besides its ability to suppress the growth of different tumor types (Arguello et al. 1998; Bible and Kaufmann 1996; Byrd et al. 1998; Carlson et al. 1996; Gojo et al. 2002; Konig et al. 1997; Patel et al. 1998), this compound was shown to induce cell cycle arrest and apoptosis in acute myeloid leukemia (AML) in correlation with STAT3 repression (Nelson et al. 2011). Flavopiridol is currently in clinical trials for the treatment of different cancers including AML and ALL (Blum et al. 2010).

Conclusion

The transcription factor STAT3 is one of the major proteins controlling the transcriptional regulation of many genes involved in essential and housekeeping cellular functions. Its activity results from the activation of signaling pathways and depends on many factors independent from tissue specificity. Therefore, permanent activation of STAT3 triggers perturbation in many tissues, especially the deregulation of cell death and cell cycle, obviously leading to cancer genesis. Constitutive phosphorylation of STAT3 is then considered to be a potential target for the treatment of many cancers and has to be further explored. In this regard, a couple of natural compounds have revealed a potential or a clear capacity to inhibit STAT3 phosphorylation in in vitro and in vivo investigations, leading to the downregulation of target genes in correlation with the induction of apoptosis and the inhibition of cell proliferation. These effects are generally correlated with the inhibition of the phosphorylation of tyr705. This phosphorylation is known to regulate STAT3 dimerization, leading to its translocation to the nucleus and interaction with DNA. Conversely, the role of ser727 phosphorylation of STAT3 is poorly understood, but it is assumed to be positively and negatively involved in the transcriptional activity of STAT3. Few inhibitors of STAT3 with inhibitory activity on ser727 phosphorylation have been reported. Indeed, original articles describing natural inhibitors of STAT3 usually report the effect on tyr705 phosphorylation, as well as of related tyrosine kinases such as JAK or Src, whereas the effect on ser727 is only marginally described. We can assume that most of the compounds are inactive on ser727 or have likely not been tested so far. Nevertheless, among natural inhibitors, curcumin was shown to inhibit phosphorylation of STAT3 at both tyr705 and ser727 residues in biliary cancer cells (Prakobwong et al. 2011). Interestingly, the inhibition of ser727 phosphorylation has been shown to induce apoptosis in Human B-leukemia and other cell lines constitutively expressing phosphorylated STAT3 in ser727 by curcubitacin-I (JSI-124) (Ishdorj et al. 2010). Obviously, B-leukemia cells are known to express activated STAT3 with constitutive phosphorylation in ser727 but not in tyr705, supporting the role of ser727 phosphorylation in the oncogenic activity of STAT3 and suggesting this residue as a potential target for natural inhibitors of STAT3 activity.

As observed, the molecular structures of the active compounds as inhibitors of STAT3 phosphorylation differ. Therefore, it may be considered difficult to establish a real relationship between the molecular structures and the inhibitory activity of these natural compounds. However, these compounds act through very similar mechanisms. On the one hand, most of them appear as non-specific inhibitors of STAT3 activity because they do not target functional regions of the protein. On the other hand, they are all described as acting via the inhibition of upstream kinases, such as JAK2 or Src, or as inducers of Src homology 2 phosphatases. One can consider that constitutive activation of STAT3 especially occurs in cancer cells, which would allow for targeting of cancer cells with specific inhibitors of P-STAT3. Nevertheless, the issue concerning the efficiency of very specific inhibitors has to be considered because the action of such molecules would likely be prevented by the continuous stimulation of signaling pathway-mediated STAT3 activation. Indeed, constitutive phosphorylation of STAT3 results from these upstream kinase activities due to mutations or hypersensitivity of cancer cells to stimulatory cytokines. However, inhibiting P-STAT3 at the source of signaling pathways would be challenging because healthy cells would also be affected, unless there is a way to accurately target only tumor cells. Moreover, it must be mentioned that most of the natural compounds described here have been shown to inhibit STAT3 phosphorylation and related signaling pathways in in vitro assays. The effects may be obviously not reproducible in vivo due to the artifacts that occur in cell culture including product half-life or product modifications.

In conclusion, it is unknown what the future holds in terms of alternative therapeutics to inhibit cell proliferation through the inhibition of STAT3 activation. However, the fact that there is an abundance of natural compounds with inhibitory properties against this transcription factor should constitute the molecular basis for the synthesis of more efficient molecules. Some of these compounds have already shown in vivo efficiency against tumors, revealing the necessity of investigating and screening such natural molecules that possess an undeniable promising future in anticancer therapeutics and chemoprevention.